Cabozantinib Active in RAI-Refractory Thyroid Cancer Cabozantinib Active in RAI-Refractory Thyroid Cancer
Cabozantinib has shown activity in the treatment of radioactive iodine-refractory differentiated thyroid carcinoma and could offer an option in addition to sorafenib and lenvatinib.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Health | Hematology | Iodine | Thyroid | Thyroid Cancer